Hims & Hers Health, Inc. (HIMS)
| Market Cap | 9.05B |
| Revenue (ttm) | 2.21B |
| Net Income (ttm) | 133.79M |
| Shares Out | 227.65M |
| EPS (ttm) | 0.54 |
| PE Ratio | 74.06 |
| Forward PE | 63.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,363,257 |
| Open | 38.90 |
| Previous Close | 38.40 |
| Day's Range | 38.52 - 39.87 |
| 52-Week Range | 23.97 - 72.98 |
| Beta | 2.40 |
| Analysts | Hold |
| Price Target | 44.56 (+12.07%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $44.56, which is an increase of 12.07% from the latest price.
News
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
The regulatory changes surrounding the weight loss treatment industry are having a large impact on Hims & Hers (HIMS 1.83%) stock.
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product of...
Hims & Hers: The Growth Story Is Outside GLP-1s
Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization ...
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and...
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authori...
Hims & Hers names ex-FDA official Deb Autor as first policy chief
Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Office...
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
Hims & Hers Health, Inc. (NYSE: HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall...
Hims & Hers Bets on Lab Testing to Boost Growth
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
2 Strong Healthcare Stock Picks for Growth Investors
The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.
2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors
These stocks have a lot more to offer than GLP-1 success. Eli Lilly is one of the oldest pharmaceutical companies in the world, is insanely profitable, and boasts a wide range of portfolio stars.
3 Overvalued Stocks to Sell
These are among the most overvalued stocks that Morningstar covers.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hen...
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Hims & Hers continues to generate strong revenue growth. The company said it was in active discussion with Novo Nordisk to bring back Wegovy to its platform.
Hims & Hers: GLP-1 Partnership Could Unlock Value
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho...
HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform
Hims & Hers Health Inc (NYSE:HIMS) isn't just chasing wellness trends — it's building a global health platform. At the company's third-quarter earnings call, CEO Andrew Dudum said the company's next p...
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Hims & Hers Health, Inc. ( HIMS) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conf...
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow
The telehealth platform said revenue rose 49% to $599 million in the latest quarter.
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
Hims & Hers Health, Inc. (NYSE:HIMS) shares popped after the company released its third-quarter earnings report after Monday's closing bell. Hims said it is in active discussions to make Novo Nordisk ...
Hims and Hers misses quarterly profit estimates
Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and reduced unit sales in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter...